Author/Authors :
Dadpour, Bita Addiction Research Centre - Mashhad University of Medial Toxicology, Mashhad, IR Iran , Mehrpour, Omid Addiction Research Centre - Mashhad University of Medial Toxicology, Mashhad, IR Iran , Etemad, Leila Department of Pharmacodynamy and Toxicology - School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, IR Iran , Moshiri, Mohammad Department of Pharmacodynamy and Toxicology - School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, IR Iran
Abstract :
Introduction: Chronic lead exposure is known to be a risk factor for hypertension (HTN). No specific medication is recommended for the
treatment of lead-induced hypertension (LIHTN). Case Presentation: Our patient was a male admitted with the chief complaint of chronic abdominal pain. His whole blood lead level
was reported to be 1961 μg/L. He also mentioned a previous history of HTN managed by propranolol (10 mg, TDS). He discharged himself
by giving written consent and 19 days later, he was re-admitted due to high blood pressure of 220/140 mmHg. His Blood pressure (BP) was
decreased to 180/110 mmHg with sublingual captopril; but, in maintenance therapy, higher doses of captopril could not further decrease
BP. Amlodipine was tried which was discontinued due to the patient intolerance. Prazosin was then administered in gradual increasing
doses up to 1 mg twice a day and captopril was tapered. Conclusions: We would like to suggest that LIHTN may better be managed by alpha blockers compared with converting enzyme inhibitors
